Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Santarelli, Lory; Staffolani, Sara; Strafella, Elisabetta; Nocchi, Linda; Manzella, Nicola; Grossi, Paola; Bracci, Massimo; Pignotti, Elettra; Alleva, Renata; Borghi, Battista; Pompili, Cecilia; Sabbatini, Armando; Rubini, Corrado; Zuccatosta, Lina; Bichisecchi, Elisabetta; Valentino, Matteo; Horwood, Keith; Comar, Manola; Bovenzi, Massimo; Dong, Lan-Feng; Neužil, Jiřı́; Amati, Monica; Tomasetti, Marco

doi:10.1016/j.lungcan.2015.09.021

Cited by 52 publications

(54 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel, and potentially more sensitive and specific MM biomarkers were evaluated, including MPF(31), OPN (60,64,66), fibulin-3 (70,72,73), HMGB1 (82), with promising results. In addition, a variety of deregulated miRNAs [reviewed in (109)], including the miR-score signature with prognostic significance (98), as well as different approaches based on proteomics technology, have been proposed as suitable MM markers (100,109). It is conceivable that a combination of the most performing and valuable markers validated by the ongoing studies will allow more accurate MM diagnosis and earlier detection in the near future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease.However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies. Here we review the most promising biomarkers in MM to date: mesothelin, soluble mesothelin-related peptides (SMRPs), megakaryocyte potentiating factor (MPF), Osteopontin (OPN), Fibulin-3, high mobility group B1 (HMGB1), microRNAs (miRNAs), multiplex protein signatures. The validation of these biomarkers will allow their use, alone or in combination, for monitoring individuals from cohorts at risk of MM and attaining early detection of MM that is instrumental in improving patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Also cell-free, circulating miRNAs have been suggested as biomarkers for MM (99)(100)(101). A plasma miRNA profiling was performed by comparing samples from MM patients and those from healthy controls.…”

Section: Micrornas (Mirnas)mentioning

confidence: 99%

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Surgical treatment of mesothelioma might lead to an alteration of biomarker levels as shown for mesothelin [57]. Regarding partial pleurectomy and therefore at least a substantial reduction in tumor burden, no influence of the miR-132-3p performance was observable between the study groups, also implicating that the biomarkers might be robust.…”

Section: Discussionmentioning

confidence: 99%

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma

et al. 2017

View full text Add to dashboard Cite

The use of circulating microRNAs as biomarkers has opened new opportunities for diagnosis of cancer because microRNAs exhibit tumor-specific expression profiles. The aim of this study was the identification of circulating microRNAs in human plasma as potential biomarkers for the diagnosis of malignant mesothelioma. For discovery, TaqMan Low Density Array Human MicroRNA Cards were used to analyze 377 microRNAs in plasma samples from 21 mesothelioma patients and 21 asbestos-exposed controls. For verification, individual TaqMan microRNA assays were used for quantitative real-time PCR in plasma samples from 22 mesothelioma patients and 44 asbestos-exposed controls. The circulating miR-132-3p showed different expression levels between mesothelioma patients and asbestos-exposed controls. For discrimination, sensitivity of 86% and specificity of 61% were calculated. Circulating miR-132-3p in plasma was not affected by hemolysis and no impact of age or smoking status on miR-132-3p levels could be observed. For the combination of miR-132-3p with the previously described miR-126, sensitivity of 77% and specificity of 86% were calculated. The results of this study indicate that miR-132-3p might be a new promising diagnostic biomarker for malignant mesothelioma. It is indicated that the combination of miR-132-3p with other individual biomarkers improves the biomarker performance.

show abstract

“…Several panels of biomarkers have been suggested as tools for screening and early diagnosis, clinical monitoring, prognosis and screening of MPM (60)(61)(62)(63)(64)(65)(66)(67)(68). The combinations studied are multiple: 80HdG, VEGFbeta and SMRPs (60), miR-126, in association with SMRPs (61), serum concentrations of SMRP, CA125, and CYFRA21-1 (62), combination of serum SMRP and pOPN (27), combination of SMRP and miR-103a-3p (63,64), SMRPs, miR-126 and methylated thrombomodulin promoter, Met-TM (65), fibulin-3 and SMRP (66), combination of miR-132-3 and miR-126 (48), combination of six biomarkers (SMRP-pOPN-IL6-vimentin-desmin-HGF) (56).…”

Section: Combination or Panel Of Serum Biomarkersmentioning

confidence: 99%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy. An altered expression of some proteins has been reported, useful as biomarkers, in comparative proteomic analysis of malignant pleural mesothelioma. New promising markers are nowadays under study and alone or better in combination, they'll be very helpful in diagnosing, monitoring mesothelioma patients or for screening of risk groups.

show abstract

Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Cited by 52 publications

References 42 publications

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma

Serum mesothelin and other biomarkers: what have we learned in the last decade?

Contact Info

Product

Resources

About